-transparent.png){kind=logo}
BACKGROUND Breast cancer is the leading nonhematologic cause of meningeal carcinomatosis (MC). The aim of this study was to report the outcome of patients diagnosed with breast cancer MC and treated in single institution by a high-dose intrathecal methotrexate (MTX) regimen. METHODS Ninety-one patients were diagnosed with breast cancer MC from 2000 to 2007. Intrathecal treatment was MTX 15 mg/day (days 1-5), hydrocortisone acetate (day 1) and oral folinic acid (days 1-5), repeated every 2 weeks. Patients and tumor characteristics were associated with the early clinical and biological outcome and with the overall survival (OS). RESULTS The median survival was 4.5 months (range 0-53). In multivariate analysis, adverse prognostic factors at diagnosis were performance status >2 [P = 0.006, response rate (RR) = 0.33 (0.15-0.71)], more than three chemotherapy regimens before MC diagnosis [P = 0.03, RR = 0.40 (0.19-0.93)], negative hormone receptor status [P = 0.02, RR = 0.4 (0.19-0.90)] and high Cyfra 21-1 level [P = 0.048, RR = (0.09-0.99)]. Clinical progression after one cycle and biological response after two cycles were independently associated with OS [P < 0.001, RR = 0.09 (0.02-0.37) and P = 0.003, RR = 3.6 (1.5-8.5), respectively]. We propose a prognostic score in order to define three distinct groups of prognosis. CONCLUSIONS MC presents a poor prognosis, but 1-year survival rate was 25%. This score may become a useful tool for treatment decision and clinical trials.
H Gauthier, and
M N Guilhaume, and
F C Bidard, and
J Y Pierga, and
V Girre, and
P H Cottu, and
V Laurence, and
A Livartowski, and
L Mignot, and
V Diéras
December 1979,
Onkologie,
H Gauthier, and
M N Guilhaume, and
F C Bidard, and
J Y Pierga, and
V Girre, and
P H Cottu, and
V Laurence, and
A Livartowski, and
L Mignot, and
V Diéras
December 2013,
Journal of neuro-oncology,
H Gauthier, and
M N Guilhaume, and
F C Bidard, and
J Y Pierga, and
V Girre, and
P H Cottu, and
V Laurence, and
A Livartowski, and
L Mignot, and
V Diéras
July 1978,
Cancer,
H Gauthier, and
M N Guilhaume, and
F C Bidard, and
J Y Pierga, and
V Girre, and
P H Cottu, and
V Laurence, and
A Livartowski, and
L Mignot, and
V Diéras
January 2001,
Breast cancer (Tokyo, Japan),
H Gauthier, and
M N Guilhaume, and
F C Bidard, and
J Y Pierga, and
V Girre, and
P H Cottu, and
V Laurence, and
A Livartowski, and
L Mignot, and
V Diéras
February 1984,
Mayo Clinic proceedings,
H Gauthier, and
M N Guilhaume, and
F C Bidard, and
J Y Pierga, and
V Girre, and
P H Cottu, and
V Laurence, and
A Livartowski, and
L Mignot, and
V Diéras
January 2005,
Tumori,
H Gauthier, and
M N Guilhaume, and
F C Bidard, and
J Y Pierga, and
V Girre, and
P H Cottu, and
V Laurence, and
A Livartowski, and
L Mignot, and
V Diéras
November 2006,
Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
H Gauthier, and
M N Guilhaume, and
F C Bidard, and
J Y Pierga, and
V Girre, and
P H Cottu, and
V Laurence, and
A Livartowski, and
L Mignot, and
V Diéras
January 1986,
European neurology,
H Gauthier, and
M N Guilhaume, and
F C Bidard, and
J Y Pierga, and
V Girre, and
P H Cottu, and
V Laurence, and
A Livartowski, and
L Mignot, and
V Diéras
July 1982,
Cancer,
H Gauthier, and
M N Guilhaume, and
F C Bidard, and
J Y Pierga, and
V Girre, and
P H Cottu, and
V Laurence, and
A Livartowski, and
L Mignot, and
V Diéras
September 2006,
The Lancet. Oncology,
